Stockreport

Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH) [Yahoo! Finance]

Dianthus Therapeutics, Inc.  (DNTH) 
PDF On March 4, Guggenheim increased the price target on Dianthus Therapeutics Inc. (NASDAQ:DNTH) to $200 from $100. The firm maintains its Buy rating on the stock with an [Read more]